PROM1 and colorectal carcinoma: Since CD133 can interact with EGFR and has been hypothesized to contribute to resistance to EGFR-targeting drugs [16], we also determined whether simultaneous targeting of CD133 by 293C3-SDIE would sensitize CRC cells to anti-EGFR mAb treatment.